Outlook Therapeutics, Inc. (OTLK): Price and Financial Metrics


Outlook Therapeutics, Inc. (OTLK): $1.27

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OTLK to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OTLK Stock Price Chart Interactive Chart >

Price chart for OTLK

OTLK Price/Volume Stats

Current price $1.27 52-week high $2.12
Prev. close $1.27 52-week low $0.68
Day low $1.25 Volume 465,400
Day high $1.30 Avg. volume 587,000
50-day MA $1.08 Dividend yield N/A
200-day MA $1.17 Market Cap 325.97M

Outlook Therapeutics, Inc. (OTLK) Company Bio


Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics. Outlook Therapeutics focuses on monoclonal antibodies in the disease areas of immunology and oncology aspects. Outlook Therapeutics offers its services in the United States.


OTLK Latest News Stream


Event/Time News Detail
Loading, please wait...

OTLK Latest Social Stream


Loading social stream, please wait...

View Full OTLK Social Stream

Latest OTLK News From Around the Web

Below are the latest news stories about OUTLOOK THERAPEUTICS INC that investors may wish to consider to help them evaluate OTLK as an investment opportunity.

Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference

– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the SVB Securi

Yahoo | February 7, 2023

Outlook draws bullish views at Cantor on potential FDA nod for lead asset

  • Cantor Fitzgerald launched its coverage on Outlook Therapeutics (NASDAQ:OTLK) on Monday with an Overweight recommendation and a 12-month target of $4 per share, expecting the biotech to win the FDA nod for its lead candidate, ONS-5010.
  • "We'd be buyers of the name ahead of the summer PDUFA action date," the analyst Kristen Kluska wrote, referring to the FDA action date on Aug. 29 assigned for the company's marketing application for ONS-5010 (Lytenava) in wet age-related macular degeneration (wAMD).
  • The analyst explains that Lytenava is an ophthalmic formulation of Roch...

    Seeking Alpha | February 6, 2023

Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence

Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic productsISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointments of Surendra Sharma,

Yahoo | January 19, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

Yahoo | January 11, 2023

Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast presentation on Tuesday, January 17th at 11:00 AM ETISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17,

Yahoo | January 9, 2023

Read More 'OTLK' Stories Here

OTLK Price Returns

1-mo 18.69%
3-mo 15.45%
6-mo 5.83%
1-year -7.97%
3-year 25.74%
5-year N/A
YTD 17.59%
2022 -20.59%
2021 4.62%
2020 120.34%
2019 -85.25%
2018 N/A

Continue Researching OTLK

Here are a few links from around the web to help you further your research on Outlook Therapeutics Inc's stock as an investment opportunity:

Outlook Therapeutics Inc (OTLK) Stock Price | Nasdaq
Outlook Therapeutics Inc (OTLK) Stock Quote, History and News - Yahoo Finance
Outlook Therapeutics Inc (OTLK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7948 seconds.